CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 55 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00227110
NCT00227110Phase 4Completed
CompareCT.gov

Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

The University of Texas Health Science Center at San Antonio·interventional·Posted Sep 27, 2005·Updated Oct 14, 2009

In Brief

A Phase 4 clinical trial evaluating Pioglitazone and Placebo for Nonalcoholic Steatohepatitis. Completed, enrolled 55 participants across 1 site.

Detailed Summary

To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Takeda Pharmaceuticals North America, Inc.

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2005
Enrollment StartOct 1, 2002
Primary CompletionNov 1, 2005
Study CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.8 years ago

Interventions

Pioglitazonedrug

30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.

Placebodrug

Placebo is given to match pioglitazone.